Caboxamycin, a new antibiotic of the benzoxazole family produced by the deep-sea strain Streptomyces sp. NTK 937

Hohmann, Claudia; Schneider, Kathrin; Bruntner, Christina; Irran, Elisabeth; Nicholson, Graeme; Bull, Alan T.; Jones, Amanda; Brown, Roselyn; Stach, James E. M.; Goodfellow, Michael; Beil, Winfried; Krämer, Marco; Imhoff, Johannes F.; Süssmuth, Roderich D.; Fiedler, Hans‐Peter

doi:10.1038/ja.2008.24

Cited by 166 publications

(89 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…96 Indeed, many novel bioactive compounds such as Abyssomicin, Proximicin and Caboxamycin from these new actinomycetes have been isolated. [97][98][99] Samples from anaerobic habitats, freshwater habitats, high and low temperature environments and low nutrient sites are also important sources for isolating novel actinomycetes. 100 Despite the fact that a large diversity of microorganisms are continuously isolated using traditional methods, the majority of microorganisms from the environment are unculturable in the laboratory.…”

Section: Biodiversity Of Marine Microbial Strainsmentioning

confidence: 99%

Bioprospecting microbial natural product libraries from the marine environment for drug discovery

Ashforth

Ren

et al. 2010

J Antibiot

View full text Add to dashboard Cite

Marine microorganisms are fascinating resources due to their production of novel natural products with antimicrobial activities. Increases in both the number of new chemical entities found and the substantiation of indigenous marine actinobacteria present a fundamental difficulty in the future discovery of novel antimicrobials, namely dereplication of those compounds already discovered. This review will share our experience on the taxonomic-based construction of a highly diversified and low redundant marine microbial natural product library for high-throughput antibiotic screening. We anticipate that libraries such as these can drive the drug discovery process now and in the future.

show abstract

Section: Biodiversity Of Marine Microbial Strainsmentioning

confidence: 99%

Bioprospecting microbial natural product libraries from the marine environment for drug discovery

Ashforth

Ren

et al. 2010

J Antibiot

View full text Add to dashboard Cite

show abstract

“…NTK 937, which was isolated from the same sediment sample as strain NTK 935. 2 Both strains were screened by HPLC-diode array together with a further 36 streptomycete isolates from the Canary Basin sediment and resulted in the identification of known antibiotics, such as alteramide, antimycins, chromomycin, cyclothiazomycin, elaiophylin, lysolipin and sporaviridin. Besides strains NTK 935 and NTK 937, further strains were identified as producers of unknown metabolites, which are still under investigation and will be reported in forthcoming communications.…”

Section: Discussionmentioning

confidence: 99%

“…NTK 937, which we reported recently to produce caboxamycin, a novel antibiotic with a benzoxazole scaffold. 2 Extracts of strain NTK 935 contained a metabolite having an unusual UV-vis spectrum, which was not identified by means of our in-house developed HPLC database. 3 HPLC-ESI-MS analysis revealed a molecular mass of 380, which was-together with UV-vis data-not in accordance with other natural products available in the DNP database.…”

Section: Introductionmentioning

confidence: 95%

Benzoxacystol, a benzoxazine-type enzyme inhibitor from the deep-sea strain Streptomyces sp. NTK 935

et al. 2011

Self Cite

View full text Add to dashboard Cite

Benzoxacystol, a new 1,4-benzoxazine-type metabolite, was produced by strain NTK 935, a marine member of the Streptomyces griseus 16S rRNA clade, isolated from deep-sea sediment collected from the Canary Basin. The structure of benzoxacystol was determined by mass spectrometry, NMR experiments and X-ray analysis. The compound showed an inhibitory activity against the enzyme glycogen synthase kinase 3b and a weak antiproliferative activity against mouse fibroblast cells. Keywords: 1,4-benzoxazin-3-one; glycogen synthase kinase 3b; marine Streptomyces INTRODUCTION Actinomycetes from marine sediments collected at various sites in the Atlantic and Pacific Oceans were screened by HPLC-diode array analysis for the production of novel secondary metabolites. Strain NTK 935 was isolated from the same deep-sea sediment core as Streptomyces sp. NTK 937, which we reported recently to produce caboxamycin, a novel antibiotic with a benzoxazole scaffold. 2 Extracts of strain NTK 935 contained a metabolite having an unusual UV-vis spectrum, which was not identified by means of our in-house developed HPLC database. 3 HPLC-ESI-MS analysis revealed a molecular mass of 380, which was-together with UV-vis data-not in accordance with other natural products available in the DNP database. 4 Therefore, strain NTK 935 was selected for fermentation studies, isolation and characterization of the unusual metabolite; this resulted in the identification of the novel 1,4-benzoxazine structure shown in Figure 1.This study describes the taxonomy of the producing strain, fermentation and isolation, structural elucidation and biological activity of the new benzoxazine-type metabolite, which was named benzoxacystol.

show abstract

“…NTK 937 from sediments of the Canary Basin ( Figure 9). It shows antitumour activity against gastric adenocarcinoma cell lines (AGS), hepatocellular carcinoma (HepG2) and breast carcinoma (MCF7) as well as antibacterial properties against Gram-positive bacteria [66,77]. Dermacoccus abyssi, actinomycete strains isolated from the Mariana Trench sediment, produces phenazine-type secondary metabolites (dermacozines (16)) that possess antitumour (against Marinomycin A, daryamide C, lucentamycins (A,B), mansouramycins (13) and tatrolons (Figure 8) are other antitumour compounds that have been obtained from actinomycete strains found in marine sediments [11].…”

Section: Anticancer Activity Of Actinomycete Metabolites Now and In mentioning

confidence: 99%

Biologically active secondary metabolites from Actinomycetes

Solecka¹,

Zajko²,

Postek³

et al. 2012

Open Life Sciences

113

View full text Add to dashboard Cite

AbstractSecondary metabolites obtained from Actinomycetales provide a potential source of many novel compounds with antibacterial, antitumour, antifungal, antiviral, antiparasitic and other properties. The majority of these compounds are widely used as medicines for combating multidrug-resistant Gram-positive and Gram-negative bacterial strains. Members of the genus Streptomyces are profile producers of previously-known secondary metabolites. Actinomycetes have been isolated from terrestrial soils, from the rhizospheres of plant roots, and recently from marine sediments. This review demonstrates the diversity of secondary metabolites produced by actinomycete strains with respect to their chemical structure, biological activity and origin. On the basis of this diversity, this review concludes that the discovery of new bioactive compounds will continue to pose a great challenge for scientists.

show abstract

Caboxamycin, a new antibiotic of the benzoxazole family produced by the deep-sea strain Streptomyces sp. NTK 937

Cited by 166 publications

References 25 publications

Bioprospecting microbial natural product libraries from the marine environment for drug discovery

Bioprospecting microbial natural product libraries from the marine environment for drug discovery

Benzoxacystol, a benzoxazine-type enzyme inhibitor from the deep-sea strain Streptomyces sp. NTK 935

Biologically active secondary metabolites from Actinomycetes

Contact Info

Product

Resources

About